AOTMiT Recommends Public Funding for Type 1 Diabetes Antibody Screening
The Transparency Council of AOTMiT has recommended including anti-IA2 and anti-ZnT8 antibody tests in the guaranteed benefits package, potentially simplifying diagnostic access for patients with...
The Transparency Council of AOTMiT has recommended including anti-IA2 and anti-ZnT8 antibody tests in the guaranteed benefits package, potentially simplifying diagnostic access for patients with suspected type 1 diabetes across Poland.
Table Of Content
A Critical Step Toward Universal Diagnosis
The Agency for Health Technology Assessment and Tariff System (AOTMiT) has positively evaluated the inclusion of anti-IA2 and anti-ZnT8 antibody testing into outpatient specialist care. Currently, these tests lack dedicated public funding, leaving availability dependent on individual facilities or patient out-of-pocket payments.
While this decision does not guarantee immediate implementation, it paves the way for a significant reform in Polish diabetology. The Ministry of Health must now provide the final approval to formalize these diagnostic services for children and adults.
Enhancing Detection of Autoimmune Diabetes
Type 1 diabetes is an autoimmune condition where the immune system destroys insulin-producing beta cells, a process that often begins years before symptoms emerge. Standardizing the diagnostic panel to include the ZnT8 marker is expected to increase detection efficacy to nearly 98 percent.
By expanding the diagnostic range, doctors can better differentiate type 1 diabetes from type 2 or MODY variants. This reduces ambiguous diagnoses and prevents patients from reaching a state of diabetic ketoacidosis before receiving insulin treatment.
Anticipated Benefits and Projected Costs
The proposed funding is expected to cost between 2.6 million and 3.1 million PLN annually. Experts argue that this is a minor expenditure given the potential to reduce costly hospitalizations and improve long-term patient health outcomes.
For individuals with a family history or elevated glucose levels, this shift offers a more precise risk assessment. It replaces months of uncertain observation with actionable data, enabling faster medical intervention and comprehensive specialist care.